Introduction
============

Lung cancer is one of the most common types of malignant tumor and the leading cause of cancer-associated mortality ([@b1-ijmm-42-06-3424]). The 5-year survival of patients with lung cancer is only 16.6% ([@b1-ijmm-42-06-3424],[@b2-ijmm-42-06-3424]). Non-small cell lung cancer (NSCLC) represents \~85% of all incident lung cancer cases, with adenocarcinoma, squamous cell carcinoma and large cell carcinoma as the typical histopathological types ([@b3-ijmm-42-06-3424]). Bone metastasis occurs in \~40% of NSCLC cases, resulting in serious morbidities and mortality ([@b4-ijmm-42-06-3424]). Patients with NSCLC with bone metastasis often experience severe pain, pathologic bone fracture, spinal cord compression and hypercalcemia, which result in a poor quality of life, decreased survival rates and increases in medical expenditure ([@b5-ijmm-42-06-3424]). Despite this clinical importance, the pathological mechanism of bone metastasis in lung cancer remains poorly understood.

Sclerostin domain-containing protein 1 (SOSTDC1), also known as WISE, USAG1 or ectodin, was previously studied in the context of tooth development ([@b6-ijmm-42-06-3424]), hair follicle formation ([@b7-ijmm-42-06-3424]), limb morphogenesis ([@b8-ijmm-42-06-3424]) and trigeminal ganglion formation ([@b9-ijmm-42-06-3424]). As a regulator of cell differentiation and proliferation, SOSTDC1 was identified to be associated with the development and progression of multiple types of cancer, including breast, gastric, renal and thyroid cancer ([@b10-ijmm-42-06-3424]--[@b13-ijmm-42-06-3424]). Zhou *et al* ([@b14-ijmm-42-06-3424]) indicated that SOSTDC1 inhibited thyroid cancer metastasis by regulating epithelial-mesenchymal transition (EMT). Previous studies confirmed SOSTDC1 as a suppressor of Wnt and bone morphogenic protein (BMP) signaling pathways ([@b15-ijmm-42-06-3424],[@b16-ijmm-42-06-3424]). However, Zhou *et al* ([@b14-ijmm-42-06-3424]) also suggested that SOSTDC1 may regulate phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (Erk) pathways in thyroid cancer, indicating that SOSTDC1 may participate in complex carcinogenic mechanisms. Liu *et al* ([@b17-ijmm-42-06-3424]) demonstrated that SOSTDC1 served as a tumor suppressor through inhibiting proliferation in NSCLC cells. However, the roles and mechanism of SOSTDC1 in NSCLC metastasis, in particular bone metastasis, remain unclear.

The present study detected the expression of SOSTDC1 in primary and bone metastatic lung cancer tissues, and demonstrated that SOSTDC1 expression was reduced in lung cancer bone metastatic compared with primary NSCLC tissues. Furthermore, through the overexpression or inhibition experiments on SOSTDC1, SOSTDC1 was revealed to inhibit NSCLC cell proliferation, migration, invasion, EMT and cancer cell-induced osteoclastogenesis. Finally, RNA deep sequencing was performed to predict the potential downstream targets of SOSTDC1 in NSCLC. These results indicated that SOSTDC1 may serve key roles in NSCLC bone metastasis.

Materials and methods
=====================

Clinical samples
----------------

A total of 141 paratumor lung tissues, 145 NSCLC tissues and 49 lung cancer bone metastatic tissues were collected from patients who underwent surgical resection at Changzheng Hospital of the Second Military Medical University (Shanghai, China) between January 2009 and December 2015. Clinical data of the patients including age, sex, tumor size, the 7th American Joint Committee on Cancer stage ([@b18-ijmm-42-06-3424]), pathology grade ([@b19-ijmm-42-06-3424]) and the expression level of SOSTDC1 are summarized in [Table I](#tI-ijmm-42-06-3424){ref-type="table"}. None of the patients received neoadjuvant chemotherapy or radiotherapy prior to surgery. The present study was approved by the Ethics Committee of Second Military Medical University and written informed consent was obtained from the surviving patients, or family members of those who had succumbed.

Immunohistochemistry (IHC)
--------------------------

Each tissue sample was fixed in 4% paraformaldehyde at 4°C for 24 h, dehydrated through a graded series of ethanol (75, 85, 90 and 95%) for 2 h, and finally incubated with absolute ethanol for 1 h at 4°C. Samples were then paraffin embedded, sliced into 4-*µ*m sections and stained for rabbit anti-human SOSTDC1 antibody (dilution, 1:1,000; cat. no. ab99340; Abcam, Cambridge, MA, USA). The staining was performed using the Histostain-Plus (DAB) kit (Shanghai Mingrui Biotech Co., Ltd., Shanghai, China) following the manufacturer's protocol. Briefly, sections were heated for antigen retrieval, blocked by 1% bovine serum albumin (BSA; Servicebio Inc., Wuhan, China), and incubated overnight at 4°C with the primary antibody. Subsequent to washing with PBS, the slides were incubated with the goat anti-rabbit IgG horseradish peroxidase (HRP)-conjugated secondary antibody (1:200; cat. no. sc-2004; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at room temperature for 1 h, and stained with DAB solution for 2--8 min at room temperature under an electron optical microscope (magnification, ×100). The staining intensity was scored as follows: 0, negative; 1, weakly positive; 2, moderately positive; and 3, strongly positive. The positivity was scored by percentage according to four categories: 0, \<5%; 1, 5--25%; 2, \>25--50%; 3, \>50--75%; and 4, \>75%. The staining score was generated by multiplying the staining intensity score with the percentage of positivity, and was defined as either low expression (score ≤2) and high expression (score ≥3).

Reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay
----------------------------------------------------------------------------

Total RNA of clinical samples or cultured cells were isolated using TRIzol^®^ (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and reverse transcribed into cDNA by using Prime Script™ RT Master Mix (Takara Bio, Inc., Otsu, Japan). RT was performed at 37°C for 30 min followed by incubation for 5 sec at 85°C to inactivate the reverse transcriptase using the Prime Script RT Master Mix (Takara Bio, Inc., Otsu, Japan) according to the manufacturer's protocol. For qPCR, all reactions were performed with a hot-start preincubation step of 5 min at 95°C, followed by 40 cycles of 25 sec at 95°C, 30 sec at 58°C and 20 sec at 72°C, and a final 5 min step at 72°C using SYBR-Green qPCR Master Mix (Bimake, Houston, TX, USA) on a 7900HT Fast Real-Time PCR system (Thermo Fisher Scientific, Inc.),. Expression levels were calculated using GAPDH as an internal control with the 2^−ΔΔCq^method ([@b20-ijmm-42-06-3424]). All primers are summarized in [Table II](#tII-ijmm-42-06-3424){ref-type="table"}.

Construction of SOSTDC1 overexpression and inhibition plasmids
--------------------------------------------------------------

For the SOSTDC1 overexpression plasmid, a vector pcDNA3.1+ plasmid (Shanghai GeneChem Co., Ltd., Shanghai, China) was enzyme digested by *Kpn*I and *Eco*RV (Beijing TransGen Biotech Co., Ltd., Beijing, China), and the code sequence of SOSTDC1 (5′-ATGCTTCCTCCTGCCATTCATTTCTATCTCCTTCCCCTTGCATGCATCCTAATGAAAAGCTGTTTGGCTTTTAAAAATGATGCCACAGAAATCCTTTATTCACATGTGGTTAAACCTGTTCCAGCACACCCCAGCAGCAACAGCACGTTGAATCAAGCCAGAAATGGAGGCAGGCATTTCAGTAACACTGGACTGGATCGGAACACTCGGGTTCAAGTGGGTTGCCGGGAACTGCGTTCCACCAAATACATCTCTGATGGCCAGTGCACCAGCATCAGCCCTCTGAAGGAGCTGGTGTGTGCTGGCGAGTGCTTGCCCCTGCCAGTGCTCCCTAACTGGATTGGAGGAGGCTATGGAACAAAGTACTGGAGCAGGAGGAGCTCCCAGGAGTGGCGGTGTGTCAATGACAAAACCCGTACCCAGAGAATCCAGCTGCAGTGCCAAGATGGCAGCACACGCACCTACAAAATCACAGTAGTCACTGCCTGCAAGTGCAAGAGGTACACCCGGCAGCACAACGAGTCCAGTCACAACTTTGAGAGCATGTCACCTGCCAAGCCAGTCCAGCATCACAGAGAGCGGAAAAGAGCCAGCAAATCCAGCAAGCACAGCATGAGTTAG-3′) was amplified by PCR (5 min at 94°C, followed by 35 cycles of 30 sec at 94°C, 30 sec at 60°C, 40 sec at 72°C and a final 5 min step at 72°C) and inserted into pcDNA3.1+ using a Quick-Fusion Cloning kit (Bimake) according to the manufacturer's protocol. For the SOSTDC1 short hairpin RNA (shRNA) plasmids, the vector pGenesil-1 plasmid (Shanghai GeneChem Co., Ltd.) was enzyme digested by *Hin*dIII and *Bam*H I (Beijing TransGen Biotech Co., Ltd.). The target sequences were synthesized (Genewiz Co., Ltd., Shuzhou, China) and inserted by using Quick-Fusion Cloning kit (Bimake) according to the manufacturer's protocol (40 ng plasmids combined with 40 ng shRNA fragments). The PCR primers and shRNA targets are summarized in [Table II](#tII-ijmm-42-06-3424){ref-type="table"}.

Cell lines and culture
----------------------

The NSCLC A549 and PC9 cell lines (Cell Bank of the Type Culture Collection Committee of the Chinese Academy of Science, Shanghai, China) were routinely maintained in DMEM (A549) and RPMI-1640 (PC9) (both from Invitrogen; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), respectively. The RNA samples of MRC-5, H1299, H522, H226, SK-MES-1 and H460 cells were kindly provided by Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, China. Bone marrow macrophages (BMMs) were isolated from C57/BL6 mice (n=4; Laboratory Animal Center, Second Military Medical University; male; 6--7 weeks) cultured in α-minimum essential medium (Invitrogen; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS as described previously ([@b21-ijmm-42-06-3424]). Mice were housed in a specific pathogen-free laboratory animal center at a temperature of 20--26°C in a standard atmosphere, and were kept on a 12/12 h light-dark cycle, and fed using standard rodent chow. Cells in the logarithmic growth phase were transfected using DNA Transfection Reagent (Bimake) once they reached 50--70% confluence, according to the manufacturer's protocol.

Western blot analysis
---------------------

Cells were harvested with radioimmunoprecipitation assay lysis buffer at 0°C for 30 min to obtain total proteins. Proteins were quantified using a BCA Protein Assay kit (cat. no. P0012S; Beyotime Institute of Biotechnology, Shanghai, China), then 20 *µ*g protein/lane was separated on 10% SDS-PAGE gels and transferred onto 0.22-mm nitrocellulose membranes (EMD Millipore, Billerica, MA, USA). The nitrocellulose membranes were blocked using 1% BSA for 20 min at 37°C. Subsequent to washing with TBS for 10 min at room temperature three times, the membranes were incubated overnight at 4°C with primary antibodies against SOSTDC1 (1:1,000; cat. no. ab99340; Abcam), cadherin 1 (1:1,000; CDH1; cat. no. AF7718; Affinity Biosciences, Cincinnati, OH, USA), vimentin (1:1,000; VIM; cat. no. AF7013; Affinity Biosciences), zinc finger protein SNAI (1:1,000; SNAI1; cat. no. AF6032; Affinity Biosciences) and β-actin (1:1,000; cat. no. AF7018; Affinity Biosciences). The membranes were washed with TBS for 5 min at room temperature three times. Proteins were detected through incubation of the membranes with HRP-conjugated goat anti-rabbit IgG secondary antibody (1:3,000; cat. no. sc-2004; Santa Cruz Biotechnology, Inc.) at 37°C for 2 h.

Cell Counting Kit-8 (CCK-8) assay
---------------------------------

A549 and PC9 cells were seeded in 96-well plates at an initial density of 5×10^3^ cells/well, cultured at 37°C for 0, 12, 24, 48 and 72 h, and finally assessed using the CCK-8 (Bimake). The results were measured by absorbance at 450 nm using an ELx800 microplate reader (BioTek Instruments Inc., USA).

Transwell migration and invasion assay
--------------------------------------

Transwell chambers (8 *µ*m pore size) without Matrigel^®^ (cat. no. 3422; Corning Incorporated, Corning, NY, USA) or with Matrigel^®^ (cat. no. 354480; Corning Incorporated) were used for Transwell migration or invasion assays, respectively. Cells were digested with Trypsin (Gibco; Thermo Fisher Scientific, Inc.) and counted. A total of 1×10^5^ cells in 100 *µ*l medium without FBS were plated in the upper chamber and 500 *µ*l medium supplemented with 10% FBS was placed in the bottom chambers as a chemoattractant. Non-migratory cells on the upper membrane surface were carefully removed after 24 h incubation at 37°C. Cells on the bottom surface were fixed with 4% paraformaldehyde for 20 min at room temperature, stained at room temperature with 0.1% crystal violet (1:1,000) for 30 min, then counted by capturing images from five random fields under a light microscope at magnification, ×400.

Osteoclast differentiation assay
--------------------------------

BMMs with macrophage colony-stimulating factor (M-CSF) stimulation (PeproTech, Inc., Rocky Hill, NJ, USA) as an osteoclast differentiation model. BMMs were cultured at 37°C with the conditional media from A549 or PC9 cells for 7 days. Then, cells were fixed by 4% paraformaldehyde for 20 min at room temperature and stained using a tartrate-resistant acid phosphatase (TRAP) staining kit (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) according to the manufacturer's protocol. TRAP-positive multinucleated cells containing ≥3 nuclei were counted as mature osteoclasts. The osteoclast cell numbers were counted by capturing images from 5 random fields under a light microscope at magnification, ×400.

RNA deep sequencing
-------------------

PC9 cells were harvested following transfection with OE-SOSTDC1 or OE-CTRL plasmids for 48 h using DNA Transfection reagent (Bimake) according to the manufacturer's protocol (1.6 ug DNA/1 ml culture medium). Total RNA was extracted from the cells using TRIzol reagent according the manufacturer's protocol, and subjected to RNA deep sequencing at Beijing Genomics Institute (Shenzhen, China) on the BGISEQ-500 platform. The sequence results were obtained as the fragment/kB of exons/million reads for each transcript. The pathway analyses of the results of RNA deep sequencing, including Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, were further performed by Beijing Genomics Institute.

Statistical analysis
--------------------

SPSS 19.0 statistical software (IBM Corp., Armonk, NY, USA) was used for statistical analysis. The Kaplan-Meier method was used to establish survival curves, and log-rank test was applied for comparative analysis of differences in patient survival. All data are presented as mean ± standard error of the mean (SEM). Factors measuring P≤0.1 from log-rank tests were subjected to the Cox proportional hazard analysis and calculation of the hazard ratio and 95% confidence interval. Statistics of the mean value between groups were assessed using one-way analysis of variance followed by the least significant difference method. All experiments were repeated at least three times, and representative experiments are presented. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

SOSTDC1 is downregulated in NSCLC bone metastatic tissues and associated with the survival outcomes of patients with NSCLC
--------------------------------------------------------------------------------------------------------------------------

IHC staining was performed to detect the expression of SOSTDC1 in 141 paratumor lung tissues, 145 primary NSCLC and 49 bone metastatic specimens. The results indicated that SOSTDC1 exhibited clear cytoplasmic expression, was significantly downregulated in primary NSCLC tissues compared with that in non-cancerous lung tissues, and additionally decreased in NSCLC bone metastatic tissues ([Fig. 1A and B](#f1-ijmm-42-06-3424){ref-type="fig"}). In addition, Kaplan-Meier analysis demonstrated that patients with primary NSCLC with high SOSTDC1 expression (n=75) exhibited significantly improved overall survival compared with those with low SOSTDC1 expression (n=70) ([Fig. 1C](#f1-ijmm-42-06-3424){ref-type="fig"}). Multivariate COX analysis of clinical factors additionally identified SOSTDC1 expression as an independent prognostic factor for patients with NSCLC ([Table III](#tIII-ijmm-42-06-3424){ref-type="table"}). Analysis of the association between the clinical factors and SOSTDC1 expression suggested that only T grade was significantly correlated with the SOSTDC1 expression level ([Table IV](#tIV-ijmm-42-06-3424){ref-type="table"}). The RT-qPCR assay also indicated that the mRNA level of SOSTDC1 was markedly decreased in bone metastatic specimens ([Fig. 1D](#f1-ijmm-42-06-3424){ref-type="fig"}). Then, differences in SOSTDC1 expression between lung cancer cell lines and normal lung cell line (MRC-5) were compared. It was identified that SOSTDC1 was markedly downregulated in NSCLC cancer cells compared with that in MRC-5 ([Fig. 1E](#f1-ijmm-42-06-3424){ref-type="fig"}).

SOSTDC1 overexpression inhibits NSCLC cell proliferation, migration, invasion and EMT
-------------------------------------------------------------------------------------

To detect the function of SOSTDC1 in NSCLC cells, a SOSTDC1 overexpression plasmid was constructed and transfected into A549 and PC9 cells. The efficiency of the overexpression plasmid was confirmed by PCR and western blot analysis ([Fig. 2A and B](#f2-ijmm-42-06-3424){ref-type="fig"}). The CCK-8 assay indicated that SOSTDC1 overexpression inhibited A549 and PC9 cell proliferation, and this inhibitory effect became more marked over time ([Fig. 2C and D](#f2-ijmm-42-06-3424){ref-type="fig"}). Cell migratory abilities were detected by Transwell assay, and the results demonstrated that the number of A549 and PC9 cells migrating through the chamber membrane in OE-SOSTDC1 plasmid transfection group was decreased significantly compared with that in the control group ([Fig. 2E and F](#f2-ijmm-42-06-3424){ref-type="fig"}). The invasion capability associated with SOSTDC1 expression was examined with Transwell chambers coated with Matrigel. As expected, the number of cells migrating through the membrane was markedly decreased when the expression of SOSTDC1 was upregulated in A549 and PC9 cells ([Fig. 3Gx and H](#f3-ijmm-42-06-3424){ref-type="fig"}). Knowing that the EMT process is an important factor enhancing cell migration and invasion, the expression of epithelial marker CDH1 and the mesenchymal markers VIM and SNAI1 following overexpression of SOSTDC1 was detected in A549 and PC9 cells. The results demonstrated that CDH1 was upregulated while VIM and SNAI1 were downregulated following SOSTDC1 overexpression in NSCLC cells ([Fig. 3](#f3-ijmm-42-06-3424){ref-type="fig"}), indicating that SOSTDC1 may suppress the process of EMT.

SOSTDC1 overexpression inhibits NSCLC cell-induced osteoclast differentiation
-----------------------------------------------------------------------------

To additionally investigate the role of SOSTDC1 in NSCLC bone metastasis, BMMs were selected using M-CSF stimulation for an osteoclast differentiation model. Conditional media from A549 and PC9 cells transfected with OE-CTRL or OE-SOSTDC1 plasmids were used as different stimuli during osteoclastogenesis. The TRAP staining assay indicated that BMMs treated with the conditional media from A549 and PC9 cells transfected with OS-SOSTDC1 plasmid exhibited a decreased level of TRAP positive multinucleated osteoclast formation as compared with the control ([Fig. 4A and B](#f4-ijmm-42-06-3424){ref-type="fig"}). The mRNA levels of nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), TRAP and cathepsin K (CTSK) were detected by RT-qPCR, as NFATc1, TRAP and CTSK are all markers of osteoclasts ([@b22-ijmm-42-06-3424]). The results suggested that the mRNA levels of NFATc1, TRAP and CTSK were all significantly decreased in BMMs stimulated with the conditional media from SOSTDC1 overexpressing A549 and PC9 cells ([Fig. 4C-E](#f4-ijmm-42-06-3424){ref-type="fig"}).

SOSTDC1 inhibition promotes NSCLC cell proliferation, migration, invasion and cancer cell-induced osteoclastogenesis
--------------------------------------------------------------------------------------------------------------------

To additionally confirm the role of SOSTDC1 in NSCLC, two shRNA plasmids for SOSTDC1 were constructed. RT-qPCR and western blot analysis indicated that the sh-SOSTDC1-2 plasmid exhibited an improved inhibitory effect compared with sh-SOSTDC1-1 in A549 and PC9 cells ([Fig. 5A and B](#f5-ijmm-42-06-3424){ref-type="fig"}). Therefore, the sh-SOSTDC1-2 plasmid was used for subsequent experiments. The CCK-8 assay demonstrated that the inhibition of SOSTDC1 promoted the proliferation of A549 and PC9 cells ([Fig. 5C and D](#f5-ijmm-42-06-3424){ref-type="fig"}). Transwell assays revealed that the suppression of SOSTDC1 promoted the migration and invasion of A549 and PC9 cells ([Fig. 5E and F](#f5-ijmm-42-06-3424){ref-type="fig"}). TRAP staining assay of BMMs stimulated with the conditional media from A549 and PC9 cells demonstrated that the inhibition of SOSTDC1 in NSCLC cells significantly decreased the osteoclast formation induced by the cancer cells ([Fig. 5G](#f5-ijmm-42-06-3424){ref-type="fig"}). Concurrently, RT-qPCR assays of TRAP and NFATc1 confirmed the facilitation of SOSTDC1 inhibition in osteoclastogenesis induced by A549 and PC9 cells ([Fig. 5H and I](#f5-ijmm-42-06-3424){ref-type="fig"}). All these data suggest that SOSTDC1 functioned as a tumor suppressor in NSCLC by regulating cell proliferation, migration, invasion and NSCLC-induced osteoclastogenesis.

Analysis of the potential downstream targets of SOSTDC1 in NSCLC
----------------------------------------------------------------

To investigate the mechanism of SOSTDC1 in NSCLC progression, RNA deep sequencing was performed to screen genes responsive to SOSTDC1 overexpression in PC9 cells ([Fig. 6A](#f6-ijmm-42-06-3424){ref-type="fig"}). Pathway analysis indicated that the changed genes were closely associated with cell growth and death, cell motility, and cancer ([Fig. 7](#f7-ijmm-42-06-3424){ref-type="fig"}). A selection of the altered genes \[statistical significance (P\<0.05) with the changed rate \>40%\] associated with cancer progression are exhibited in [Fig. 6B](#f6-ijmm-42-06-3424){ref-type="fig"}, and RT-qPCR assay was used to validate the decrease in P21 (RAC1) activated kinase 6 (PAK6), C-C motif chemokine ligand 3 (CCL3), B-cell translocation gene (BTG), Wnt family member 10A (WNT10A), C-X-C motif chemokine (CXC) ligand 1 (CXCL1), CXC ligand 2 (CXCL2), CXC ligand 8 (CXCL8) and CXC ligand 10 (CXCL10) mRNA expression following SOSTDC1 overexpression in A549 and PC9 cells ([Fig. 6C-J](#f6-ijmm-42-06-3424){ref-type="fig"}). These results suggest that the mechanisms of SOSTDC1 in NSCLC progression and bone metastasis require additional investigation.

Discussion
==========

The present study firstly demonstrated the downregulation of SOSTDC1 in NSCLC bone metastasis compared with primary tumors, and additionally identified that low SOSTDC1 expression in NSCLC predicted poor prognosis of the patients. Functionally, SOSTDC1 overexpression suppressed NSCLC cell proliferation, migration, invasion, EMT and cancer cell-induced osteoclastogenesis, while SOSTDC1 knockdown produced the opposite effect. In addition, RNA deep sequencing and RT-qPCR assays indicated that SOSTDC1 was associated with NSCLC progression and bone metastasis through regulating PAK6, CCL3, BTG, WNT10A, CXCL1, CXCL2, CXCL8 and CXCL10. All these results suggest that SOSTDC1 served an inhibitory role in NSCLC progression and bone metastasis.

The formation of NSCLC bone metastasis requires osteolysis and cancer growth induced by the interaction of cancer cells and osteoclasts or its precursors. Previous studies have suggested that SOSTDC1 was downregulated in various types of cancer, while the decreased expression of SOSTDC1 accelerated cell proliferation and predicted poor prognosis in gastric, thyroid and breast cancer ([@b10-ijmm-42-06-3424]--[@b12-ijmm-42-06-3424]). Zhou *et al* ([@b14-ijmm-42-06-3424]) additionally demonstrated that SOSTDC1 promoted thyroid cancer metastasis by activating EMT. In lung cancer, SOSTDC1 was also confirmed as a tumor suppressor through the regulation of cell proliferation ([@b17-ijmm-42-06-3424]). However, whether SOSTDC1 is involved in NSCLC metastasis remains unclear. SOSTDC1 was first examined in 2003 as the antagonist of BMPs (BMP 2, 4, 6 and 7) ([@b23-ijmm-42-06-3424]), and later was confirmed to serve key roles in bone remodeling by activating osteoblasts and osteoclasts ([@b24-ijmm-42-06-3424],[@b25-ijmm-42-06-3424]). Consistent with the role of BMPs in bone, SOSTDC1 deficiency accelerated fracture healing by promoting the expansion of periosteal mesenchymal stem cells ([@b26-ijmm-42-06-3424]). However, to the best of our knowledge, the role of SOSTDC1 in bone metastasis has not yet been described. Due to the potential effects of SOSTDC1 in the bone micro-environment and cancer progression, we hypothesized that SOSTDC1 was involved in the occurrence of bone metastasis. The result of the present study indicated that SOSTDC1 was downregulated in NSCLC bone metastatic lesions compared with that in primary lesions, and may suppress bone metastasis through inhibiting cell proliferation, migration, invasion, EMT and cancer cell-induced osteoclast differentiation. Knowing that EMT and bone resorption are two key processes during bone metastasis in NSCLC, SOSTDC1 may prove to a potential prognostic biomarker for NSCLC bone metastasis.

Previous studies identified SOSTDC1 as a suppressor of BMP and Wnt signaling pathways: Recently, Togo *et al* ([@b27-ijmm-42-06-3424]) demonstrated that SOSTDC1 antagonized RUNX2 during tooth development. Gopal *et al* ([@b12-ijmm-42-06-3424]) revealed that SOSTDC1 was involved in CpG methylation in gastric cancer. Zhou *et al* ([@b14-ijmm-42-06-3424]) suggested that SOSTDC1 promoted thyroid cancer progression through the regulation of the PI3K/Akt and MAPK/Erk pathways. Concurrently, SOSTDC1 was demonstrated to be repressed by estrogen ([@b28-ijmm-42-06-3424]) and E4BP4 ([@b11-ijmm-42-06-3424]), and activated by FGF signaling ([@b29-ijmm-42-06-3424]). These data indicate that SOSTDC1 may participate in complex signaling pathways. Nevertheless, the exact molecular mechanism of SOSTDC1 in NSCLC require elucidation. Therefore, RNA deep sequencing was performed in the present study to explore the potential downstream targets of SOSTDC1 in NSCLC. Notably, it was identified that besides certain components of the Wnt family, several members of the CXCL family (CXCL1/2/8/10) were downregulated following SOSTDC1 overexpression. These CXCLs were considered the downstream targets of the Erk pathway ([@b30-ijmm-42-06-3424]) and certain other pathways, including tumor necrosis factor and nuclear factor kappa-light-chain enhancer of activated B cells signaling ([@b31-ijmm-42-06-3424]), and identified as the catalyst of osteoclastogenesis and osteolysis ([@b18-ijmm-42-06-3424],[@b32-ijmm-42-06-3424],[@b33-ijmm-42-06-3424]). These results may assist in understanding the mechanism of SOSTDC1 in NSCLC bone metastasis. Altogether, the present study demonstrated that SOSTDC1 served a potential role in inhibiting NSCLC bone metastasis, which may provide useful insights for future studies on the treatment of NSCLC bone metastasis. Limitations of the present study included the absence of an *in vivo* experiment of SOSTDC1 in NSCLC bone metastasis, and the incomplete clinical data of the samples, in particular the absence of treatment choice, which may have affected the prognosis of the patients. Additional studies are required to confirm the clinical significance and the molecular mechanism of SOSTDC1 in NSCLC and bone metastasis.

In conclusion, the present study demonstrated that SOSTDC1 was downregulated in NSCLC bone metastasis compared with that in primary tumors, and functioned as a potential tumor suppressor by regulating cell proliferation, migration, invasion, EMT and cancer cell-induced osteoclast differentiation. In addition, a number of potential downstream target genes of SOSTDC1 were identified that may be associated with bone metastasis in NSCLC cells. These data may assist in developing novel diagnostic and treatment strategies for NSCLC bone metastasis.
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![SOSTDC1 is downregulated in NSCLC bone metastasis and associated with the survival outcome of patients with NSCLC. (A) IHC staining of SOSTDC1 in paratumor lung tissue, primary NSCLC and NSCLC bone metastasis tissues. Scale bars on the full images represent 100 *µ*m and those on the magnified images represent 25 *µ*m. (B) Statistical analysis of IHC staining. (C) Kaplan-Meier analysis of SOSTDC1 expression associated with overall survival in patients with NSCLC. (D) RT-qPCR assay of mRNA level of SOSTDC1 in clinical samples. (E) RT-qPCR assay of mRNA level of SOSTDC1 in various NSCLC cell lines and normal lung cell line. ^\*\*\*^P\<0.001. RT-qPCR, reverse transcription quantitative polymerase chain reaction; SOSTDC1, sclerostin domain-containing protein 1; NSCLC, non-small cell lung cancer; IHC, immunohistochemistry.](IJMM-42-06-3424-g00){#f1-ijmm-42-06-3424}

![Overexpression of SOSTDC1 inhibits NSCLC cell proliferation, migration and invasion. (A and B) Confirmation of SOSTDC1 overexpression following transfection in A549 and PC9 cells by (A) PCR and (B) western blot analysis. (C) CCK-8 assay of A549 cells following transfection with OE-SOSTDC1 or OE-CTRL plasmids. (D) CCK-8 assay of PC9 cells following transfection. (E) Transwell migration assay of A549 cells following transfection with OE-SOSTDC1 or OE-CTRL plasmids. (F) Transwell migration assay of PC9 cells following transfection. (G) Transwell invasion assay of A549 cells following transfection with OE-SOSTDC1 or OE-CTRL plasmids. (H) Transwell invasion assay of PC9 cells following transfection. ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001. NSCLC, non-small cell lung cancer; SOSTDC1, sclerostin domain-containing protein 1; PCR, polymerase chain reaction; CCK-8, Cell Counting Kit 8; OE, overexpression; CTRL, control.](IJMM-42-06-3424-g01){#f2-ijmm-42-06-3424}

![Overexpression of SOSTDC1 inhibits the epithelial-mesenchymal transition process in non-small cell lung cancer cells. The expression levels of epithelial marker CDH1 and the mesenchymal markers VIM and SNAI1 were detected by western blot analysis following the overexpression of SOSTDC1 in A549 and PC9 cells. SOSTDC1, sclerostin domain-containing protein 1; CDH1, cadherin 1; VIM, vimentin; SNAI1, zinc finger protein SNAI1; OE, overexpression; CTRL, control.](IJMM-42-06-3424-g02){#f3-ijmm-42-06-3424}

![Overexpression of SOSTDC1 inhibits NSCLC cell-induced osteoclast differentiation. (A) Mouse BMMs were seeded and cultured with conditional medium containing macrophage colony-stimulating factor (10 ng/ml) from A549 or PC9 cells transfected with OE-CTRL or OE-SOSTDC1 plasmids for 7 days. Then, TRAP staining was performed. (B) TRAP-positive osteoclasts were counted. (C) RT-qPCR analysis of mRNA level of TRAP in BMMs. (D) RT-qPCR analysis of NFATc1. (E) RT-qPCR analysis of CTSK. ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001. SOSTDC1, sclerostin domain-containing protein 1; OE, overexpression; CTRL, control; TRAP, tartrate-resistant acid phosphatase; RT-qPCR, reverse transcription quantitative polymerase chain reaction; BMMs, bone marrow macrophages; NFATc1, nuclear factor of activated T cells, cytoplasmic 1; CTSK, cathepsin K; CM, conditioned media.](IJMM-42-06-3424-g03){#f4-ijmm-42-06-3424}

![Inhibition of SOSTDC1 promotes NSCLC cell proliferation, migration, invasion and cancer cell-induced osteoclastogenesis. (A and B) Confirmation of SOSTDC1 suppression following transfection with shRNA plasmids in A549 and PC9 cells by (A) RT-qPCR and (B) western blot analysis. (C) CCK-8 assay of A549 cells following transfection with SOSTDC1 shRNA plasmids. (D) CCK-8 assay of PC9 cells following transfection with SOSTDC1 shRNA plasmids. (E) Transwell migration assay of A549 and PC9 cells following transfection with sh-CTRL or sh-SOSTDC1 plasmids. (F) Transwell invasion assay of A549 and PC9 cells following transfection with sh-CTRL or sh-SOSTDC1 plasmids. (G) The counting of TRAP-positive osteoclasts in BMMs cultured with conditional medium from A549 or PC9 cells transfected with sh-CTRL or sh-SOSTDC1 plasmids. (H) RT-qPCR analysis of mRNA level of TRAP in BMMs. (I) RT-qPCR analysis of NFATc1. ^\*^P\<0.05, ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001. SOSTDC1, sclerostin domain-containing protein 1; shRNA, short hairpin RNA; CTRL, control; RT-qPCR, reverse transcription quantitative polymerase chain reaction; TRAP, tartrate-resistant acid phosphatase; BMMs, bone marrow macrophages.](IJMM-42-06-3424-g04){#f5-ijmm-42-06-3424}

![Analysis of potential relevant downstream genes of SOSTDC1 in NSCLC cells. (A) RNA deep sequencing of PC9 cells was performed following transfection with OE-CTRL or OE-SOSTDC1 plasmids. (B) The fold-change of a selection of the genes associated with tumor progression in RNA sequencing. (C-J) RT-qPCR assay was performed to detect changes in mRNA expression of several genes involved in cancer following transfection with OE-CTRL or OE-SOSTDC1 plasmids in A549 and PC9 cells, including (C) PAK6, (D) CCL3, (E) BTC, (F) WNT10A, (G) CXCL1, (H) CXCL2, (I) CXCL8 and (J) CXCL10. ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001. OE, overexpression; CTRL, control; SOSTDC1, sclerostin domain-containing protein 1; shRNA, CTRL, control; PAK6; P21 (RAC1) activated kinase 6; CCL3, C-C motif chemokine ligand 3; BTC, betacellulin; WNT10A, Wnt family member 10A; CXCL1, C-X-C motif chemokine (CXC) ligand 1; CXCL2 CXC ligand 2; CXCL8, CXC ligand 8; CXCL10, CXC ligand 10.](IJMM-42-06-3424-g05){#f6-ijmm-42-06-3424}

###### 

Pathway analysis of the results of RNA deep sequencing in PC9 cells transfected with OE-CTRL or OE-SOSTDC1 plasmids. (A) Gene Ontology analysis. (B) Kyoto Encyclopedia of Genes and Genomes pathway analysis. OE, overexpression; CTRL, control; SOSTDC1, sclerostin domain-containing protein 1.

![](IJMM-42-06-3424-g06)
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###### 

Patient characteristics.

  Patient characteristics     Disease phenotypes   
  --------------------------- -------------------- -----------
  Age, years                  60.5±10.0            53.0±10.1
  Sex, male/female            104/41               25/24
  Types, AD/SCC/unknown       72/73/0              30/7/12
  Size, cm                    4.6±1.9              4.5±1.7
  Pathology grade, I/II/III   16/96/33             --
  T grade, 1/2/3/4            26/87/28/4           --
  N grade, 0/1/2/3            82/36/23/4           --
  AJCC grade, 1/2/3           55/54/36             --
  SOSTDC1, high/low           75/70                14/35

NSCLC, non-small cell lung cancer; AD, adenocarcinoma; SCC, squamous cell carcinoma; AJCC, American Joint Committee on Cancer; SOSTDC1, sclerostin domain-containing protein 1; T, tumor; N, node.

###### 

Polymerase chain reaction primers used in the present study.

  Gene name       Forward                                                                                    Reverse                                                                                    Product length, bp
  --------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ --------------------
  Human SOSTDC1   AACAGCACGTTGAATCAAGCC                                                                      GCCATCAGAGATGTATTTGGTGG                                                                    123
  Mouse TRAP      GCCCTTACTACCGTTTGC                                                                         TCTCGTCCTGAAGATACTGC                                                                       351
  Mouse NFATc1    CTCACCACAGGGCTCACTA                                                                        GATGGCTCGCATGTTATTT                                                                        284
  Mouse CTSK      AGTAGCCACGCTTCCTAT                                                                         CATCCACCTTGCTGTTAT                                                                         182
  Human PAK6      ACCAATAGGCATGGAATGAAGG                                                                     GCGGTCGGAAAGAGGAGTTG                                                                       247
  Human CCL3      CCGTCACCTGCTCAGAATC                                                                        CTGCTCGTCTCAAAGTAGTCA                                                                      183
  Human BTC       CCTGGGTCTAGTGATCCTTCA                                                                      CTTTCCGCTTTGATTGTGTGG                                                                      131
  Human WNT10A    GGAGACTCGCAACAAGATCCC                                                                      CGATGGCGTAGGCAAAAGC                                                                        80
  Human CXCL10    CCAAGGGTACTAAGGAATC                                                                        AGGTAGCCACTGAAAGAAT                                                                        165
  Human CXCL2     GAGGCTGAGGAATCCAAGA                                                                        CACAGAGGGAAACACTGCA                                                                        253
  Human CXCL1     CCCCAAGAACATCCAAAGT                                                                        GGAACAGCCACCAGTGAGC                                                                        202
  Human CXCL8     TGGCAGCCTTCCTGATTT                                                                         CTTCTCCACAACCCTCTG                                                                         245
  Human GAPDH     GGAGTCCACTGGCGTCTTCA                                                                       GGGGTGCTAAGCAGTTGGTG                                                                       191
  Mouse GAPDH     TGTTTCCTCGTCCCGTAG                                                                         CAATCTCCACTTTGCCACT                                                                        108
  SOSTDC1-CDS     AACTTAAGCTTGGTACATGCTTCCTCCTGCCATTCAT                                                      GCCACTGTGCTGGATCTAACTCATGCTGTGCTT                                                          652
  SOSTDC1-sh1     GTGGAAAGGACGCGGCGGGAACTGCGTTCCACCAAATATTCAAGACGTATTTGGTGGAACGCAGTTCCTTTTTTCCCGGGACGCGTTA   TAACGCGTCCCGGGAAAAAAGGAACTGCGTTCCACCAAATACGTCTTGAATATTTGGTGGAACGCAGTTCCCGCCGCGTCCTTTCCAC   88
  SOSTDC1-sh2     GTGGAAAGGACGCGGCGGCATTTCAGTAACACTGGACTTTCAAGACGAGTCCAGTGTTACTGAAATGCTTTTTTCCCGGGACGCGTTA   TAACGCGTCCCGGGAAAAAAGCATTTCAGTAACACTGGACTCGTCTTGAAAGTCCAGTGTTACTGAAATGCCGCCGCGTCCTTTCCAC   88

SOSTDC1, sclerostin domain-containing protein 1; TRAP, tartrate-resistant acid phosphatase; NFATc1, nuclear factor of activated T cells, cytoplasmic 1; CTSK, cathepsin K; PAK6; P21 (RAC1) activated kinase 6; CCL3, C-C motif chemokine ligand 3; BTC, betacellulin; WNT10A, Wnt family member 10A; CXCL1, C-X-C motif chemokine (CXC) ligand 1; CXCL2 CXC ligand 2; CXCL8, CXC ligand 8; CXCL10, CXC ligand 10; CDS, coding sequence; sh, short hairpin.

###### 

Univariate and multivariate analyses of different prognostic factors for overall survival in 145 patients with non-small cell lung cancer.

  Prognostic factors            Univariate analysis   Multivariate analysis                                                                                    
  ----------------------------- --------------------- ----------------------- -------------------------------------------------------- ------- --------------- ------------------------------------------------------
  Age (\>60 vs. ≤60)            1.519                 0.845--2.731            0.162                                                    --      --              --
  Sex (female vs. male)         0.690                 0.357--1.333            0.269                                                    --      --              --
  Types (AD vs. SCC)            1.277                 0.709--2.299            0.416                                                    --      --              --
  Size, cm (\>5 vs. ≤5)         1.838                 1.030--3.281            0.040[a](#tfn3-ijmm-42-06-3424){ref-type="table-fn"}     1.778   0.918--3.441    0.088
  Pathology grade (II vs. I)    4.181                 0.990--17.661           0.052                                                    2.621   0.603--11.394   0.199
  Pathology grade (III vs. I)   4.439                 0.975--20.202           0.054                                                    3.072   0.669--14.113   0.149
  T grade (3--4 vs. 1--2)       2.216                 1.225--4.011            0.009[a](#tfn3-ijmm-42-06-3424){ref-type="table-fn"}     0.525   0.134--2.057    0.355
  N grade (1--3 vs. 0)          1.912                 1.075--3.402            0.027[a](#tfn3-ijmm-42-06-3424){ref-type="table-fn"}     1.063   0.520--2.175    0.866
  AJCC grade (2 vs. 1)          0.939                 0.421--2.097            0.879                                                    0.644   0.263--1.573    0.334
  AJCC grade (3 vs. 1)          3.619                 1.802--7.270            \<0.001[a](#tfn3-ijmm-42-06-3424){ref-type="table-fn"}   2.445   1.112--5.376    0.026[a](#tfn3-ijmm-42-06-3424){ref-type="table-fn"}
  SOSTDC1 (high vs. low)        0.449                 0.248--0.812            0.008[a](#tfn3-ijmm-42-06-3424){ref-type="table-fn"}     0.505   0.276--0.922    0.026[a](#tfn3-ijmm-42-06-3424){ref-type="table-fn"}

P\<0.05. HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; SOSTDC1, sclerostin domain-containing protein 1; T, tumor; N, node.

###### 

Associations between clinical factors and SOSTDC1 expression.

  Characteristics   SOSTDC1 expression   P-value   
  ----------------- -------------------- --------- ------------------------------------------------------
  Age, years                                       0.096
   \>60             42                   34        
   ≤60              28                   41        
  Sex                                              0.581
   Male             52                   52        
   Female           18                   23        
  Types                                            1.000
   AD               35                   37        
   SCC              35                   38        
  Size, cm                                         0.856
   \>5              20                   23        
   ≤5               50                   52        
  Pathology grade                                  0.133
   I                4                    12        
   II               50                   46        
   III              16                   17        
  T grade                                          0.029[a](#tfn4-ijmm-42-06-3424){ref-type="table-fn"}
   1--2             49                   64        
   3--4             21                   11        
  N grade                                          0.135
   0                35                   47        
   1--3             35                   28        
  AJCC grade                                       0.185
   1                23                   32        
   2                25                   29        
   3                22                   14        
  Survival                                         0.008[a](#tfn4-ijmm-42-06-3424){ref-type="table-fn"}
   Yes              39                   58        
   No               31                   17        

P\<0.05. SOSTDC1, sclerostin domain-containing protein 1; AJCC, American Joint Committee on Cancer; AD, adenocarcinoma; SCC, squamous cell carcinoma; T, tumor; N, node.
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